Table 3.
Comparison of EUS-FNA biopsy outcomes
| Franseen needle (n=86), n (%) | Conventional end-cut type needle (n=64), n (%) | P | |
|---|---|---|---|
| Technical success | 86 (100) | 64 (100) | 1.000 |
| Diagnostic yield | 73 (85) | 42 (75) | 0.006 |
| Diagnosis | |||
| GIST | 37 (51) | 27 (64) | |
| Leiomyoma | 13 (18) | 8 (20) | |
| Schwannoma | 5 (7) | 1 (2) | |
| Neuroendocrine tumor | 3 (4) | 0 | |
| Ectopic pancreas | 4 (5) | 4 (10) | |
| Lymphoma | 3 (4) | 1 (2) | |
| Sarcoma | 5 (7) | 0 | |
| Others* | 3 (4) | 1 (2) | |
| Number of passes, median (quantile) | 2 (1–2) | 3 (3–4) | <0.001 |
| Surgical resection | 42 (49) | 29 (45) | 0.669 |
| Adverse events | 1 (1) | 0 | 1.000 |
*Others consist of 1 gastric adenocarcinoma, 1 accessory spleen, 1 hemangioma, and 1 esophageal squamous cell carcinoma. GIST: Gastrointestinal stromal tumor